Results of administering B.C.G. to patients with melanoma.
D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000627:therapeutic use; D001772:Blood Cell Count; D002464:Cell Migration Inhibition; D002699:Chlorambucil / Q000627:therapeutic use; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D006801:Humans; D007104:Immune Adherence Reaction; D007136:Immunoglobulins / Q000302:isolation & purification; D007167:Immunotherapy; D008207:Lymphatic Metastasis; D008213:Lymphocyte Activation; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009669:Nose Neoplasms / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D012882:Skin Tests
D000912:Antibodies, Neoplasm; D001500:BCG Vaccine; D007136:Immunoglobulins; D002699:Chlorambucil